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To the Editor: 34 
 35 
Twenty five percent of older adults in the U.S. have type 2 diabetes, which increases 36 
their risk for cognitive decline.1, 2 This risk disproportionately affects African Americans 37 
because they have higher rates of diabetes than Whites and worse glycemic control, 38 
which magnifies their risk.3  These disparities contribute to why African Americans have 39 
twice the rate of Alzheimer’s disease as Whites.4 There are now 1 million older African 40 
Americans with diabetes in the U.S. and their number will double by 2030.5 This will 41 
multiply the burden of cognitive impairment in older African Americans and necessitates 42 
preventive interventions.   43 
 44 
We are conducting an ongoing randomized controlled trial to test the efficacy of 45 
Behavioral Activation to reduce cognitive decline in African Americans with Mild 46 
Cognitive Impairment.  Behavioral Activation is a standardized, evidence-based 47 
treatment that is often used to treat depression.6  We have uniquely applied this 48 
approach to increase participation in physical, cognitive, and social activities in order to 49 
preserve cognition.  The attention control treatment is Supportive Therapy, which 50 
facilitates personal expression but contains no other active elements.  Race-concordant 51 
community health workers deliver 6 in-home treatment sessions of both interventions.  52 
Because of our interest in diabetes and cognition, we examined treatment effects on the 53 
subgroup of participants with diabetes who have had 12 month assessments (n = 35).   54 
  55 
Methods: 56 
At baseline and 12 months (masked to treatment assignment), we administered the 57 
Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT) and the Uniform Data 58 
Set (UDS) Neuropsychological Battery, which includes tests assessing verbal memory, 59 
attention, semantic memory, language, processing speed, visuospatial ability, and 60 
executive function.  Standardized z scores from the component UDS tests yield the 61 
UDS-Composite Score (UDS-CS), which reflects global cognition.  Our pilot data 62 
indicate that a decrement of 0.45 UDS-CS points translates clinically to the inability to 63 
balance a checkbook, do laundry, shop, or prepare meals.   64 
  65 
Results:  The average age of participants was 75.1 years (SD 6.8); 28 (80%) were 66 
women.  The Table shows that participants who received Behavioral Activation had 67 
improved scores over 12 months in 2 cognitive domains: episodic memory (HVLT 68 
score) and executive function/processing speed [Digit Symbol Substitution Test 69 
(DSST)].  Supportive Therapy controls had no comparable improvements.  On the UDS-70 
CS, a greater proportion of participants who received Behavioral Activation compared to 71 
Supportive Therapy improved by ≥ 0.45 points [40.0% vs. 21.1%; OR:  2.50 (.55 - 72 
11.33)], and fewer declined by ≥ 0.45 points [6.7% vs. 21.1%; OR:  0.27 (.03 - 2.70)].  73 
There were no significant changes in other neuropsychological test scores. 74 
  75 
Discussion: 76 
The treatment trends observed across three different cognitive measures in this sample 77 
of older African Americans with diabetes and Mild Cognitive Impairment suggest that 78 
Behavioral Activation may preserve cognition in this high risk group.  The sample is 79 
small, however, and the analysis is underpowered to detect treatment group 80 
differences.  Nevertheless, these preliminary findings concur with the results of previous 81 
studies indicating that physical, cognitive, and social activity may prevent cognitive 82 
decline, and extend these findings now to older African Americans with diabetes.7  The 83 
latter finding is important because the number and longevity of this population, and their 84 
risk for progressive cognitive decline and dementia, are increasing. 85 
 86 
The Behavioral Activation treatment approach simultaneously targets two entrenched 87 
health problems in older African Americans (i.e., diabetes and impaired cognition), and 88 
may prevent cognitive decline by increasing cognitive (e.g., problem-solving) and 89 
physical (e.g., exercise) activities and perhaps by improving glycemic control.  These 90 
two mechanisms are plausible because physical and cognitive inactivity, as well as poor 91 
glycemic control, increase the risk of cognitive decline.8,9  Because no disease-92 
modifying treatment for Alzheimer’s disease now exists, if an early nonpharmacologic 93 
treatment like Behavioral Activation prevents cognitive decline even by one year, it will 94 
greatly reduce the personal and societal costs of Alzheimer’s disease in older African 95 
Americans.10   96 
ACKNOWLEDGMENTS   97 
Conflict of Interest Disclosures: 98 
Elements of 
Financial/Personal 
Conflicts 
BWR 
  
RJC 
  None No None No 
Employment or 
Affiliation 
        
          
Grants/Funds         
          
Honoraria         
          
Speaker Forum         
          
Consultant         
          
Stocks         
          
Royalties         
          
Expert Testimony         
          
Board Member         
          
Patents         
          
Personal 
Relationship 
        
 99 
Author Contributions 100 
BWR:  Study concept and design; analysis and interpretation of data; and preparation 101 
of the manuscript. 102 
RJC:  Study concept and design; analysis and interpretation of data; and preparation of 103 
the manuscript. 104 
 105 
Sponsor’s Role 106 
None. 107 
 108 
REFERENCES 109 
1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes 110 
Statistics fact sheet: general information and national estimates on diabetes in the 111 
United States, 2005.  112 
 113 
2. Mayeda ER, Whitmer RA, Yaffe K. Diabetes and cognition.  Clin Geriatr Med 2015; 114 
31: 101–115. 115 
 116 
3. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in African 117 
Americans. 2005. Bethesda, MD: U.S. Department of Health and Human Services, 118 
National Institutes of Health; 2005. NIH Publication No. 02-3266. 119 
  120 
4. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers 121 
Dement. 2010;6(2):158-194. PMID: 20298981. 122 
 123 
5. Administration on Aging. A statistical profile of black older Americans aged 65+. 124 
http://www.aoa.gov/Aging_Statistics/minority_aging/Facts-on-Black-Elderly-125 
plain_format.aspx. 2009. Accessed August 1, 2013. 126 
 127 
6. Kanter JW, Manos RC, Bowe WM, Baruch DE, Busch AM, Rusch LC. What is 128 
behavioral activation? A review of the empirical literature. Clin Psychol Rev. 2010.  129 
 130 
7.  Blazer DG, Yaffe K, Liverman CT, eds. Cognitive Aging: Progress in Understanding 131 
and Opportunities for Action. Washington, DC: National Academies Press; 2015. 132 
http://www.iom.edu/cognitiveaging. Accessed April 14, 2015. 133 
 134 
8. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive 135 
decline among older adults without dementia. Arch Neurol. 2012;69(9):1170-1175. 136 
 137 
9. Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, et al.  Hyperglycemia 138 
modulates extracellular amyloid-β concentrations and neuronal activity in vivo.  J Clin 139 
Invest 2015; 125:  2463–2467. 140 
 141 
10. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of 142 
Alzheimer's disease in the United States. Alzheimers Dement. 2011;7(1):61-73. 143 
 144 
Table:  Cognitive Scores at Baseline and 12 Months by Treatment Group  145 
 146 
Behavioral Activation                  Baseline     Month 12      paired t     df      p-value 147 
(n=16)      148 
 149 
HVLT *                                             1.1  (1.7)       2.9 (2.9)       -2.56        15     .022 150 
       151 
DSST                         24.2 (11.7) 29.6 (11.3)     -2.20        13      .047   152 
        153 
 154 
Supportive Therapy    155 
(n=19)                                         156 
        157 
HVLT                                     1.6  (2.0)   2.6 (2.9) -1.62        18      .122 158 
        159 
DSST                         28.2 (11.5) 28.8 (12.1)      -.38       15      .708  160 
 161 
______________________________________________ 162 
HVLT = Hopkins Verbal Learning Test 163 
DSST = Digit Symbol Substitution Test 164 
* mean; (SD); higher scores indicate better cognitive function.   165 
 166 
